FRBRX Mutual Fund (Franklin Biotechnology Discovery Fund Class R6) is managed by Franklin Templeton Investments (US) with $6.2M in net assets. FRBRX expense ratio is 0.67%, holding 98 positions across sectors including Health Care, Unknown, Financials. Inception date: 2013-05-01.

FRBRX performance shows a YTD return of 20.41%. The 1-year return is 91.56% and the 5-year return is 13.42%. FRBRX dividend yield stands at 1.86%, paid annually.

FRBRX top holdings include Gilead Sciences Inc (6.2%), Amgen Inc. (4.8%), Vertex Pharmaceuticals Inc (4.7%), Jazz Pharmaceuticals Plc. (4.6%), Regeneron Pharmaceuticals, Inc. (4.4%). View all FRBRX holdings, sector breakdown, or dividend history.

FRBRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. FRBRX alternatives are available via the screener, along with tax-loss harvesting opportunities.